Approval · Notice of Compliance 19281 · 2017
BAT: Notice of Compliance 19281
Issued May 9, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19281
- Date
- May 9, 2017
- Company
- Emergent Biosolutions Canada IncWinnipeg, Manitoba, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BAT | 02459612 | Restricted Access |
Medicinal ingredients
- BOTULINUM ANTITOXIN SEROTYPE A 4,500 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE B 3,300 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE C 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE D 600 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE E 5,100 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE F 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE G 600 UNIT per VIAL